OBJECTIVE: To assess the effects of BMI at baseline and on-treatment weight change on the lipid-lowering ef®cacy of diet plus ®bric acid derivatives (®brates) in hypercholesterolemic adults. SUBJECTS: 6003 participants in a Belgian General Practitioners Trial, an open-label, prospective study conducted in a primary care setting. MEASURES: Effect of initial BMI, on-treatment weight change, or lipid values at baseline on percentage changes in low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Multiple linear regression models, including initial BMI, on-treatment weight change, age, gender, and baseline lipid values, were ®tted to control the in¯uences exerted by these variables on each other. RESULTS: Reductions in LDL-C after diet plus ®brate treatment for 12 weeks were inversely related to initial BMI and to TG levels at baseline, and were positively associated with baseline LDL-C concentrations and with on-treatment weight change (P`0.001 for all analyses). Decreases in TG related negatively with initial BMI (P 0.012), and positively with weight loss (P 0.011) and TG at baseline (P`0.001). Increases in HDL-C were negatively associated with initial BMI (P 0.012) and with baseline TG (P`0.001). CONCLUSIONS: The LDL-C lowering ef®cacy of ®brates is inversely related to initial BMI, and is positively associated with on-treatment weight loss.
Introduction
Fibric acid derivatives (®brates) are a widely used group of lipid-lowering drugs. Their primary action is to decrease plasma levels of triglyceride (TG)-rich lipoproteins through reduced lipolysis in adipose tissue, inhibition of hepatic very-low-density lipoprotein synthesis and/or secretion, and activation of lipoprotein lipase. 1 It is a class effect of these drugs to increase high-density-lipoprotein cholesterol (HDL-C) in most individuals. Fibrates stimulate low-density-lipoprotein (LDL) receptor-dependent clearance and reduce the amount of small, dense LDL, the fraction which is potentially more atherogenic due to its susceptibility to peroxidation.
1±3
In the Helsinki Heart Study, a 5 y primary prevention trial, a 34% reduction in the incidence of coronary heart disease (CHD) was observed in dy-slipidemic men treated with the ®brate gem®bro-zil. 4 Almost all the bene®t was however restricted to a high-risk subgroup of overweight patients (BMI b 26 kg m
72
) with TG b 204 mg/dl ( b 2.3 mmol/l) and HDL-C`42 mg/dl (`1.08 mmol/l) at baseline, 5 a lipoprotein pro®le that is frequently observed in visceral obesity. 6 Post hoc analyses of the Helsinki Heart Study have suggested that the increase in HDL-C and decrease in LDL-C levels were more pronounced in subjects with body mass index below the median value. 7 We have therefore assessed ®brate ef®cacy on blood lipid concentrations as a function of initial BMI in a data set of 6003 participants in a Belgian General Practitioners Trial (BGPT), 8 a prospective study of the management of hypercholesterolemia in a primary care setting. In addition, we have evaluated the effects of on-treatment weight change on ®brate ef®cacy.
Methods

Subjects
The data presented here were derived from the Belgian General Practitioners Trial (BGPT). The design and descriptive results of BGPT have been published elsewhere. 8 Brie¯y, this prospective study, conducted by 1198 general practitioners, has evaluated the 1991 Belgian healthcare regulations that have imposed ®brates as ®rst-line drugs in dietresistant dyslipidemic subjects. A total of 6745 consecutive patients (37% male) older than 21 y with primary dyslipidemia, de®ned as total choles-terol b 290 mg/dl ( b 7.49 mmol/l) and triglycerides 400 mg/dl (`4.52 mmol/l) after a 12 week lipidlowering diet, entered the 12 week diet plus ®brate treatment phase. Instructions for diet modi®cation, based on the Step I diet, 9 had been given immediately after initial screening to study participants by their general practitioners. The type of ®brate was chosen by the general practitioners, and ®brate dosages used were those recommended by manufacturers: beza®brate 200 mg three times daily (12% of patients); cipro®brate 100 mg daily (36%); feno®-brate 100 mg three times daily (43%); and gem®bro-zil 600 mg twice daily (9%). At week 12, only those patients eligible for reimbursement of HMG CoA reductase inhibitor (statin) use according to local stepped-care regulations (n 3311) were enrolled in a subsequent 12 week diet plus simvastatin phase.
The current analysis of BGPT data was restricted to 6003 patients of the ®brate cohort for whom complete data on age, gender, BMI before and after treatment, and lipid pro®les were available. A similar evaluation was not performed in the simvastatin cohort which was a highly selected subgroup of patients and, therefore, might not have been a representative sample of untreated hypercholesterolemic patients in Belgian general practices.
Statistical analyses
Descriptive data at baseline were evaluated by oneway analyses of variance (age and lipid levels), and by the Mantel test for trend in proportions.
Mean percentage changes in lipid concentrations after diet plus ®brate treatment were calculated for three BMI classes at baseline (BMI`25; 25 to 29.9; and 530 kg m 72 ) and for three strata of on-treatment weight change (50 kg, namely stable weight or weight gain; 70.1 to 71.9 kg; and 572.0 kg).
Multiple linear regression analyses (least-squares method) were performed to assess the respective in¯uences of BMI at baseline and of on-treatment weight change on variations in lipid values during the diet plus ®brate treatment. 10 These analyses provided simultaneously adjusted scores for all covariates included in the models: initial BMI, on-treatment weight change, age, gender, and baseline lipid values. For modelling purposes, initial BMI, change in weight, age, and baseline lipid values were used as continuous variables. Distributions of continuous variables tended to normality, and no collinearity or nearcollinearity existed between variables. No interaction of statistical signi®cance was observed between BMI at baseline and on-treatment weight change.
Results and Discussion
A mean 3.8% reduction in total cholesterol was observed during the preliminary diet-only phase of BGPT. 8 The main characteristics at baseline, namely after the diet-only phase, of the 6003 patients (37% male) included in the present analysis and strati®ed according to BMI and gender, are summarized in 9 59% of ®brate-treated patients in BGPT were at high-risk for coronary heart disease (CHD), 8 which re¯ects the clustering of CHD risk factors other than LDL-C in this population. As expected, prevalences of elevated triglyceride levels, high blood pressure and diabetes mellitus were signi®cantly related to BMI in both men and women (Mantel test for trend; P`0.0001 for each risk factor).
Mean percentage changes in blood lipids during diet plus ®brate treatment as a function of initial BMI and on-treatment weight change are listed in Table 2 . Mean weight change during the 12 week diet plus ®brate treatment phase was 70.95 AE 1.9 kg in men, and 70.80 AE 1.9 kg in women. Mean (median) weight Table 3 . Reductions in LDL-C, LDL-C/HDL-C, and triglycerides were inversely related to BMI at baseline. Increase in HDL-C was less pronounced in those with higher initial BMI. On-treatment decrease in weight was positively associated with reductions in LDL-C, LDL-C/HDL-C, and triglycerides. The magnitude of the reduction in LDL-C with therapy was positively related with LDL-C level at baseline, and was negatively associated with baseline triglyceride value. Similar results were obtained after exclusion of diabetic or hypertensive patients.
Conclusions
LDL-C lowering ef®cacy of ®brates was inversely related to initial BMI, and positively associated with concomitant weight loss. In this context, it should be noted that ®brates exert a favourable in¯uence on nonlipid CHD risk factors related to hemostatic imbalance such as elevated plasminogen activator inhibitor-1 and ®brinogen. 3, 11, 12 Both risk factors are highly prevalent in abdominal obesity, and are associated with the degree of hyperinsulinism. 13, 14 Hyperinsulinism and insulin resistance are often related to low HDL and high triglyceride levels, and to disturbed haemocoagulation factors in obesity. Overweight subjects might therefore bene®t from ®brates by mechanisms other than their LDL-C lowering action only. 5 In the recently published Beza®brate Coronary Atherosclerosis Intervention Trial (BECAIT), 15 beza®brate was shown to slow the progression of focal coronary atherosclerosis, and to reduce coronary events in young male survivors of myocardial infarction (median age 42 years; median BMI 27.3 kg m
72
). In BECAIT, there were signi®cant treatment effects of beza®brate on plasma ®brinogen, serum TG, and HDL-C, whereas LDL-C concentrations did not change.
